Scarica l'app Stockscreener
1.33
4.72%
0.06
Dopo l'orario di chiusura:
1.30
-0.03
-2.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.27
Aprire:
$1.3
Volume 24 ore:
5.08M
Relative Volume:
0.72
Capitalizzazione di mercato:
$401.66M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-0.8867
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
-3.62%
1M Prestazione:
-22.22%
6M Prestazione:
+13.68%
1 anno Prestazione:
+10.83%
Intervallo 1D:
$1.29
$1.39
Intervallo di 1 settimana:
$1.25
$1.46
Portata 52W:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.33 | 401.66M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
108.03 | 187.72B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 128.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 102.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 47.52B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-06 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio - geneonline.com
Pacific Biosciences of California technology maps cancer structural variants in single platform advance - Traders Union
PACB,TAL Options - Finviz
PacBio and DNAstack collaborate on global HiFi genome network hub - MSN
PACB,TAL Volatility & Greeks - Finviz
Chart Watch: Will Pacific Biosciences of California Inc outperform during market ralliesWeekly Earnings Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Why The PacBio (PACB) Investment Story Is Shifting As Analysts Cut Targets And Flag Risks - Yahoo Finance
HiFi sequencing enables automatic detection of 5mC and 6mA, Pacific Biosciences of California asserts - Traders Union
Pacific Biosciences Secures Key Patent License, Ends Litigation - TipRanks
Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com
Patent deal locks in protections for Pacific Biosciences (NASDAQ: PACB) with PGI - Stock Titan
Pacific Biosciences of California, Inc. Announces Chief Accounting Officer Changes, Effective March 21, 2026 - marketscreener.com
PACB - Finviz
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
PACB Analyst Rating Downgrade by Barclays to Underweight | PACB Stock News - GuruFocus
Pacific Biosciences of California (NASDAQ:PACB) Receives Underweight Rating from Barclays - MarketBeat
Barclays downgrades Pacific Biosciences stock rating on catalysts By Investing.com - Investing.com Canada
Barclays downgrades Pacific Biosciences stock rating on catalysts - Investing.com UK
PacBio Announces the Appointment of Chris Gibson to the Board of Directors - Sahm
Barclays downgrades Pacific Biosciences of California (PACB) - MSN
Pacific Biosciences of California unveils HiFi sequencing for comprehensive multiomic analysis - Traders Union
PacbBio Announces Appointment of Christopher Gibson to Board of Directors and Member of the Science and Technology Committee, Effective March 3, 2026 - marketscreener.com
PacBio Adds AI-Driven Drug Discovery Leader to Board - TipRanks
Pacbio announces the appointment of Chris Gibson to the board of directors - marketscreener.com
PacBio Appoints New Board Member - Intellectia AI
AI biotech leader Chris Gibson joins PacBio (PACB) board of directors - Stock Titan
AI drug discovery founder from Recursion joins PacBio board - Stock Titan
Pacific Biosciences of California, Inc. $PACB Shares Sold by ARK Investment Management LLC - MarketBeat
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 By Investing.com - Investing.com Canada
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 - Investing.com
Pacific Biosciences of California (NASDAQ:PACB) Insider Christian Henry Sells 12,497 Shares - MarketBeat
PRISM 2026 set to shape genomics future, Pacific Biosciences of California asserts - Traders Union
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - Finviz
Intuitive Surgical Expands Direct Operational Presence in Europe - Finviz
Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB) - Yahoo Finance
Equity awards to Pacific Biosciences (PACB) officer disclosed - Stock Titan
PACB (PACB) grants James R. Gibson II 667,696 options and 333,848 RSUs - Stock Titan
Pacific Biosciences (PACB) officer receives large option and RSU awards - Stock Titan
Large equity grants to PacBio (PACB) executive highlight retention focus - Stock Titan
Christian Henry sells 472,667 PACB shares (PACB) on Form 144 - Stock Titan
PacBio and DNAstack Join Forces to Launch Worldwide HiFi Genome Network Hub - Bitget
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - Yahoo Finance
Pacific Biosciences of California enables automatic epigenetic data in HiFi sequencing runs - Traders Union
Pacific Biosciences of California backs San Diego event to strengthen rare disease awareness - Traders Union
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Finviz
PACB,TAL Revenue Breakdown - Finviz
Pacific Biosciences of California joins IRDiRC to advance rare disease research - Traders Union
Vestmark Advisory Solutions Inc. Sells 692,663 Shares of Pacific Biosciences of California, Inc. $PACB - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pacific Biosciences of California (PACB) Stock Analysis: A 53% Upside Awaits in the Genomic Sequencing Arena - DirectorsTalk Interviews
Pacific Biosciences Of California Files For Mixed Shelf Size - TradingView
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):